Orserdu (Elacestrant HCl) Patent Expiration, LOE Window & CMS Spending

Orserdu (Elacestrant HCl) by Stemline Therapeutics: FDA Orange Book core substance LOE 2038-01-05, 0 AB generics, $293.5M 2024 CMS Part D & Medicaid spend, and $7,123 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorStemline Therapeutics
FDA Application & PathwayN217639 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2038-01-05
Last Listed Patent or Exclusivity Date2038-01-05
Orange Book Patents (*PED Extensions)7 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$293.5M
2024 Medicare Part D Spend$258.8M
2024 Medicaid Spend$34.7M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($7,123 intro WAC)